What is the recommended screening approach for thalassemia?

Screening Test for Thalassemia

The recommended screening approach for thalassemia begins with complete blood count (CBC) focusing on mean corpuscular volume (MCV) and red blood cell distribution width (RDW), followed by hemoglobin electrophoresis, with genetic testing reserved for confirmation and identification of specific mutations.

Initial Screening Strategy

The most practical and cost-effective initial screening uses readily available hematologic parameters:

• MCV (Mean Corpuscular Volume): A low MCV indicates microcytic anemia and serves as the primary screening indicator 1
• RDW (Red Blood Cell Distribution Width): Critical for differentiating thalassemia from iron deficiency
  • Low MCV + RDW ≤14.0% suggests thalassemia minor
  • Low MCV + RDW >14.0% suggests iron-deficiency anemia 1

This combination is particularly useful because thalassemia typically causes less variation in red blood cell size compared to iron deficiency 1.

Enhanced Screening Parameters

For neonates and more comprehensive screening, additional parameters improve diagnostic accuracy 2:

• Elevated RBC count with low MCV, MCH (mean corpuscular hemoglobin), and MCHC (mean corpuscular hemoglobin concentration)
• Reticulocyte parameters: Including reticulocyte count (RET#) and immature reticulocyte fraction (IRF)
• A combined model using RBC, MCHC, RET#, and IRF achieved 72.7% sensitivity and 89.2% specificity for differentiating α- from β-thalassemia 2

Population-Specific Screening Approaches

High-Risk Populations (Southeast Asian, Mediterranean, African descent)

Parents should be screened by MCV measurement - carriers typically have MCV <80 fL 3. In high-prevalence regions like Southeast Asia, where alpha-thalassemia accounts for 28-55% of nonimmune hydrops fetalis, this is particularly critical 3.

Universal vs. Cascade Screening

Recent evidence from high-prevalence populations demonstrates important limitations of traditional cascade screening:

• Traditional MCV-based cascade screening misses 33.8% of α-thalassemia carriers and 12.5% of β-thalassemia carriers 4
• Traditional screening detected only 71.4% of α-high-severity couples at risk for Hb Bart's hydrops fetalis 5
• NGS-based universal screening detected carriers at 4.74 times the rate of traditional screening (15.05% vs. 3.18%) 5

Genetic Testing Confirmation

When initial screening suggests thalassemia:

Traditional Genetic Methods

• PCR-based detection identifies 95-98% of thalassemia carriers 6
• Detects common deletions and mutations in HBA1/2 and HBB genes

Next-Generation Sequencing (NGS)

NGS should be considered for comprehensive screening, particularly in high-prevalence populations, despite higher cost (USD 21.00 vs. USD 3.90 for traditional screening) 5. NGS advantages include:

• Detection of silent α-thalassemia and β++-thalassemia variants substantially under-detected by traditional methods 5
• Identification of rare mutations (HBA2:c.34A>C, HBA1:c.354_355insATC, rare triplicates) 7
• Single-step determination of cis/trans configuration of allelic mutations 7
• Critical for patients with atypical presentations who lack typical microcytic hypochromia 7

Third-Generation Sequencing (TGS)

Shows 5.04% higher detection rate compared to PCR-based methods and excels at detecting:

• Rare HBA1/2 mutations and compound mutations
• Rare HBB mutations
• Complex structural variants 7, 6

Critical Screening Algorithm

1. Initial CBC with focus on MCV and RDW
2. If MCV low (<80 fL) and RDW ≤14.0%: Proceed to hemoglobin electrophoresis
3. Hemoglobin electrophoresis to identify abnormal hemoglobin patterns
4. Genetic testing for:
   • Confirmation of carrier status
   • Identification of specific mutations
   • Couples at risk (both partners carriers)
   • Prenatal diagnosis when indicated

Common Pitfalls to Avoid

• Do not rely solely on MCV cutoff screening - this approach misses significant proportions of carriers, particularly silent α-thalassemia variants 5, 4
• Do not assume normal blood counts exclude thalassemia - some rare mutations (HBA2:c.34A>C, HBA1:c.354_355insATC, HBB:c.170G>A) do not show typical microcytic hypochromia 7
• Always perform both blood routine tests AND hemoglobin electrophoresis before genetic testing to minimize missed diagnoses 7
• In prenatal screening, parents with MCV <80 fL require DNA testing for alpha-thalassemia to prevent Hb Bart's hydrops fetalis 3

Family Screening Recommendations

When a proband is identified:

• Screen siblings and spouse (especially in consanguineous relationships)
• Test children only if both parents are carriers or in consanguineous marriages
• Heterozygous carriers should be screened for disease phenotype 8